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Introduction
Randomised controlled trials are, in most scenarios, the best
scientific method for evaluating the efficacy of treatment.1
However, some randomised controlled trials may have poor
external validity. Therefore, complementing any evidence on
treatment efficacy from randomised controlled trials with that
from observational studies is often valuable.2 In this article, we
draw attention to a method, known as the regression
discontinuity design (RDD), that examines treatment efficacy
by using observational data.We describe how this method could
be useful to evaluate treatment strategies in primary care and
outline the concept of RDD to a clinical audience.
We consider an observational dataset in which information is
available on a particular treatment and a specific, continuous,
outcome variable. Our interest lies in determining the effect of
the treatment on the outcome. Furthermore, treatment allocation
occurs according to the value of a chosen, continuous,
“assignment variable,” whereby patients are given the treatment
if their assignment variable lies above a pre-specified
“threshold.” For example, a drug for hypertension (the treatment)
designed to reduce blood pressure (the outcome) might be given
only to those patients whose systolic blood pressure (the
assignment variable) lies above 140 mm Hg (the threshold). In
clinical practice, the threshold may not always be fixed.
An RDDmakes use of the treatment threshold and assumes that
individuals whose assignment variable lies “just above” or “just
below” this threshold belong to the same population. With this
assumption, the threshold might be seen as a random
intervention that assigns the treatment to people whose
assignment variable lies just above the threshold and withholds
treatment from those whose assignment variable lies just below
the threshold. We note that, unlike in a randomised controlled
trial, this is not true randomisation, but it may be interpreted as
a form of quasi-randomisation in an observational setting.
Hence, the RDD could be used, in some cases, to estimate the
effect of treatment on a specific outcome.
Since its inception in the 1960s in educational economics,3 the
RDD has been applied in labour economics,4 politics,5
psychology,6 and other areas.7 However, with a few notable
exceptions,8-13 the RDD has yet to be exploited fully to improve
understanding of treatment efficacy in medicine. Previous
applications of RDDs to healthcare have tended to tailor the
design to specific problems and have often used RDDs for health
economic analyses rather than for the assessment of a specific
treatment effect. We focus on how an RDD may be used with
observational data within a medical context more generally,
where a treatment is applied at a given threshold, such as the
prescription of a drug according to specific guidelines (for
example, National Institute for Heath and Care Excellence
(NICE) guidelines). In addition, we discuss the problem of
non-adherence to treatment. Throughout, we use the prescription
of statins on the basis of cardiovascular risk score as an example
to illustrate these concepts.
Example: prescription of statins in UK
primary care
Statins are one of the most widely prescribed classes of drugs
in UK primary care, accounting for more than £800m (€500m;
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$664m) of National Health Service expenditure in 2011.14 The
effect of statins in primary prevention of cardiovascular disease
has been widely investigated in randomised controlled trials
and observational studies.15 16
NICE guidance on the use of statins for the primary prevention
of cardiovascular disease suggests that statins should be
prescribed to people whose risk of experiencing a cardiovascular
event in the subsequent 10 years exceeds 20% (revised
downwards to a 10% risk score threshold in July 2014), as
calculated using an appropriate cardiovascular risk indicator
(for example, the Framingham risk calculator at www.
framinghamheartstudy.org/risk-functions/cardiovascular-disease/
10-year-risk.php.17 Hence, the RDD could be used to estimate
the effect of statins on low density lipoprotein cholesterol
concentration for people around this 20% threshold under the
assumption that those “just below” and “just above” the
threshold are similar. If this assumption is valid, then we have
two groups of treated and untreated individuals whom we
consider to belong to the same population. In this example, the
assignment variable is the 10 year cardiovascular risk score, the
outcome variable is the low density lipoprotein cholesterol
concentration, and the threshold is a 10 year cardiovascular risk
score of 20%. Figure 1⇓ illustrates some example plots of low
density lipoprotein cholesterol concentration against
cardiovascular risk score. In plots A, B, and C, patients receive
treatment only when they lie above the 20% risk score threshold.
In plot D, for some patients (represented by the square icons),
treatment is contrary to that inferred from their risk scores.
Figure 1⇓ panels A-C show different approaches to the analysis
of these measurements, when treatment is applied strictly
according to the guidelines. A “naïve” approach to estimating
the treatment effect would be to take the difference in sample
mean low density lipoprotein cholesterol concentrations between
people above and people below the threshold, within a particular
distance, d, either side of the threshold (fig 1⇓, panel A). The
distance, d, defines the population to which the RDD is applied
and quantifies the notion of similar people being just below and
just above the threshold.
This naïve approach to estimation depends on the chosen value
of d. A more appropriate estimate of the treatment effect at the
threshold would be obtained by fitting linear regression models
on either side of the threshold,18 because one might assume a
linear relation between risk score and low density lipoprotein
cholesterol concentration. If a constant relation between risk
score and low density lipoprotein cholesterol concentration is
assumed, then two separate linear regression models with the
same slope would be fitted, one on each side of the threshold
(fig 1⇓, panel B). Then, the difference in fitted low density
lipoprotein cholesterol concentrations at the 20% threshold,
estimated using these two models, would be an estimate of the
effect of statins on low density lipoprotein cholesterol
concentration. If the slopes cannot be considered the same below
and above the threshold, as in figure 1⇓ panel C, then linear
regressionmodels with different slopes should be fitted on each
side of the threshold or, perhaps, more flexible models could
be considered.19
Figure 1⇓ panels A-C represent situations in which guidelines
are strictly adhered to. In this context, an RDD is termed
“sharp.” Many situations may exist in which guidelines are not
interpreted strictly. For statin prescriptions, individual general
practitioners may prescribe statins by using other information
about patients, or patients might request a prescription for a
statin irrespective of their risk score. In such scenarios, there
will be people below the threshold who receive the treatment
and people above the threshold who do not. In this case, the
RDD is termed “fuzzy.” Figure 1⇓ panel D shows an example
plot from a fuzzy RDD, where the square icons represent those
patients who received treatment contrary to that indicated by
their 10 year cardiovascular risk score.
Generally, most RDDs in clinical settings will be fuzzy and
must account for the possibility that the threshold does not
correspond to a strict separation between treated and untreated
patients. A fuzzy RDD is analogous to a randomised controlled
trial with partial compliance: there are patients allocated to a
treatment arm (equivalent to being above the threshold in an
RDD) who have not received a treatment and patients allocated
to the control arm (below the threshold in an RDD) who have
received a treatment. These patients are unlikely to represent a
random sample in either a randomised controlled trial or an
RDD setting. This problem can be alleviated by using a method
for estimation of treatment effect that accounts for whether or
not a patient actually receives the treatment above or below the
threshold. This estimate is termed a “local average treatment
effect,”19 20 and we view this as the treatment effect estimate
from a sharp RDD but re-weighted to account for the fuzziness
in the RDD. This method may be unreliable in some cases,
typically where the threshold is not strongly associated with the
treatment received. In this scenario, an RDD may not be
appropriate for the estimation of a treatment effect.
Our estimates of treatment effect depend on the threshold being
a reliable indicator of patients’ treatment. Figure 2⇓ provides
some guidance on appropriate data plots to consider when
attempting to use an RDD. Such plots can be helpful in exploring
whether the threshold defines an acceptable separation between
treated and untreated patients. In the statins example, if we plot
risk score against low density lipoprotein cholesterol
concentration and observe an obvious “jump” or discontinuity
at the threshold level, this indicates that the threshold defines
an appropriate point at which an RDD might be used.
Discussion
Considerable scope exists for use of an RDD to evaluate effects
of treatment by using observational data. An RDD is useful
when treatment is applied according to a strictly defined rule,
linked to a variable measured on a continuous scale (such as
blood pressure or cardiovascular risk score). An RDD may be
used in scenarios in which the treatment rule is not adhered to
strictly, provided that the assignment variable gives a reasonable
indication of the treatment received. A major advantage of an
RDD is that it may be used to evaluate the efficacy of treatments
in “real world” populations outside randomised controlled trials.
Furthermore, an RDD may be a first step in establishing
estimates of treatment effect in sub-populations that have been
excluded from randomised controlled trials or for areas in which
such trials would not be feasible.
Naturally, an RDD does not necessarily represent a quick fix
for all problems encountered when using observational data to
estimate treatment effects. The assumption that individuals
around the threshold are similar could be violated and should
be assessed using context specific information. Other factors
such as choosing the size of the region around the threshold for
the RDD and the possible changing nature of the assignment
variable over time are important. One should ensure that the
threshold defines an appropriate point at which treatment is
started. Plots of the assignment variable against the outcome
variable, such as those in figure 2⇓, would help to establish this.
Finally, as with most observational studies, the problems of
possible unobserved confounding andmissing data usually need
careful consideration.
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Overall, an RDD applied to observational data represents a
pragmatic approach to estimation of treatment effect in clinical
practice. The rich data available from electronic health records,
if used appropriately, may allow the effectiveness of NHS or
government defined prescription rules to be evaluated.
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Summary points
Regression discontinuity designs are not commonly applied to observational data in medicine but may represent a useful method to
estimate the causal effect of a treatment in a clinical setting
Under particular assumptions, such designs can be used to evaluate the effectiveness of NHS or clinical treatment guidelines in a
pragmatic manner, using observational data from clinical practice
In addition, these designs may be useful in verifying whether results seen in randomised controlled trials are applicable to wider
populations, in the examination of treatment efficacy for populations who are under-represented in randomised controlled trials, or for
scenarios in which such trials are not feasible
Figures
Fig 1 Graphical representations of various regression discontinuity design (RDD) scenarios using simulated data with 10
year cardiovascular risk score as assignment variable and low density lipoprotein (LDL) cholesterol concentration as outcome
variable. d represents arbitrary maximum distance from 20% cardiovascular risk score threshold at which data points would
be included in associated RDD analysis
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Fig 2 Useful exploratory plots of assignment variable against outcome variable with threshold marked by the solid line.
Panel A shows obvious sharp discontinuity at threshold where regression discontinuity design (RDD) could be used. B
shows fuzzy scenario in which RDD could be used with some accounting for fuzziness. C shows no obvious discontinuity
at threshold; one would not naturally consider RDD here
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